Docetaxel (Taxotere®) in the neo-adjuvant setting in non-small-cell lung cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Mattson, K ^a,b  

^a Div Pulmon Dis Clin Physiol   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Docetaxel; Neo adjuvant; Non small cell lung cancer; Taxotere

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; DISEASE COURSE; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0032692161     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S69     Document Type: Conference Paper

References (26)

1. Klastersky J, Burkers R, Choi N et al. Induction chemotherapy for NSCLC: A consensus report. Lung Cancer 1991; 7: 15-7.
2. Rosell R, Font A, Pifarre A et al. The role of induction (neo-adjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996; 109: 102S-6S.
3. Tonato M. The role of neo-adjuvant chemotherapy in NSCLC. Chest 1996; 109: 93S-5S.
4. Pastorino U. Benefits of neo-adjuvant chemotherapy in NSCLC. Chest 1996; 109: 96S-101S.
5. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 678-80.
6. Rosell R, Gumez-Codina J, Camps C et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-8.
7. Cerny T, Kaplan S, Puvlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 1994; 70: 384-7.
8. Burris H, Eckhardt J, Fields S et al. Phase II trials of (Taxotere) with non-small-cell lung cancer. Proc Am Soc Clin Oncol 1993; 12:335 (Abstr 1116).
9. Francis P, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
10. Fossella F, Lee JS. Murphy WK. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238-44.
11. Harper P. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small-cell lung cancer. Semin Oncol 1997; 24 (4, Suppl 14): 30-2.
12. Mattson K, Ten Velde G, Krofta K et al. Taxotere as neo-adjuvant therapy for radically-treatable stage III NSCLC. Preliminary results of an international phase III study. Proc Am Soc Clin Oncol 1998.
13. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. Phase I-II study of cisplatin and docetaxel in non-small-cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 1087.
14. Belani CP, Bonomi P, Dobbs T et al. Multicenter phase II study of docetaxel and cisplatin combinations in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 462a (Abstr 1660).
15. Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 750-8.
16. Le Chevalier T, Belli L, Monnier A et al. Phase I trial of docetaxel and cisplatin in advanced NSCLC: An interim analysis. Proc Am Soc Clin Oncol 1995; 14: 1059.
17. Androulakis N, Korousis C, Kakolyris S et al. First-line treatment of non-small-cell lung cancer with docetaxel and cisplatin. Ann Oncol 1996; 7 (Suppl 5): 98-9 (Abstr 468P).
18. Griesinger F, Kern L, Binder L et al. Phase II study of (Taxotere)/ carboplatin with pharmacokinetics and dynamics in NSCLC for downstaging and palliation stage IV. Eur J Cancer 1997; 33 (Suppl 8): S232 (Abstr 1050).
19. Scagliotti GV, Ferrari G, Novello S. Neo-adjuvant chemotherapy prior to surgery in stage III non-small-cell lung cancer. Monaldi Arch Chest Dis 1997; 52 (6): 531-4.
20. Spiro SG. An overview of recent overviews in the treatment of non-small-cell lung cancer. Monaldi Arch Chest Dis 1997; 52 (6): 529-30.
21. Isokangas O-P, Joensuu H, Halme M et al. Paclitaxel (Taxol®) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC. Lung Cancer 1998; 20: 127-31
22. Johnson DH, Turrisi A, Pass HI. Combined modality treatment for locally advanced NSCLC. In Lung Cancer, Principles and Practice. Philadelphia, PA: Lippincott-Raven Chapter 55, 863-73.
23. Saarinen A, Jekunen A, Halme M et al. A phase II study of docetaxel in advanced non-small-cell lung cancer. Anti-Cancer Drugs 1996; 7: 1-3.
24. 2 non-small-cell lung cancer: Analysis of the literature. Lung Cancer 1998; 19: 3-13.
25. 0-1) non-small-cell lung cancer. Proc Am Assoc Clin Oncol 1998; 17: 1738.
26. Aamdal S, Wibe E, Hallen MN et al. Phase I study of concomitant docetaxel (Taxotere®) and radiation in locally advanced non-small-cell lung cancer. Proc Am Assoc Clin Oncol 1997; 16: A1654.